The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the design of the Phase I/II EXCEED-ET trial (NCT05482971), which aims to evaluate the efficacy of ropeginterferon alfa-2b in adults with essential thrombocythemia (ET), discussing the primary and secondary endpoints of the study.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
